Results show that various classes of antidepressants exert improving effects on cognitive function across several cognitive domains .
Specifically , studies suggest that SSRIs , the SSRE tianeptine , the SNRI duloxetine , vortioxetine and other antidepressants such as bupropion and moclobemide may exert certain improving effects on cognitive function in depression , such as in learning and memory and executive function .
The few non-pharmacological studies conducted employing cognitive orientated treatments and cognitive remediation therapy show promising results for the improvement of cognitive impairment in depression .
Cognitive dysfunction is of clinical significance and exerts longst and ing implication on patients ׳ function .
Pharmacological and non-pharmacological treatments of cognitive dysfunction are emerging .
This review evaluates pharmacological and non-pharmacological treatments of cognitive impairment primarily in the domains of memory , attention , processing speed and executive function in clinical depression .
Antidepressants and cognition: comparative effects of moclobemide, viloxazine and maprotiline
The respective effects of three antidepressant drugs ( moclobemide , 450 mg/j ; viloxazine , 300 mg/j ; maprotiline , 150 mg/j ) on vigilance , attention , and memory were compared . Young depressed out patients ( n=46 ) entered a double-blind , r and omised , monocentre clinical trial lasting for 6 weeks . Drug actions were assessed through the regular determination of critical flicker fusion point ( CFF ) , reaction times ( SRT ) , and a battery to measure memory components . None of the three drugs caused deterioration in cognitive functions . On the other h and , moclobemide improved both vigilance and attention ( CFF , SRT ) and some crucial components of memory ( general memory scores , delayed word recall , recognition of familiar faces ) . This effect was rapid , stable , and superior to those of viloxazine and maprotiline . It may be explained by moclobemide 's selective and reversible inhibition of monoamine oxidase A , as well as by the lack of any anticholinergic action
Results show that various classes of antidepressants exert improving effects on cognitive function across several cognitive domains .
Specifically , studies suggest that SSRIs , the SSRE tianeptine , the SNRI duloxetine , vortioxetine and other antidepressants such as bupropion and moclobemide may exert certain improving effects on cognitive function in depression , such as in learning and memory and executive function .
The few non-pharmacological studies conducted employing cognitive orientated treatments and cognitive remediation therapy show promising results for the improvement of cognitive impairment in depression .
Cognitive dysfunction is of clinical significance and exerts longst and ing implication on patients ׳ function .
Pharmacological and non-pharmacological treatments of cognitive dysfunction are emerging .
This review evaluates pharmacological and non-pharmacological treatments of cognitive impairment primarily in the domains of memory , attention , processing speed and executive function in clinical depression .